Full history for every metric is available with a Kvantra account

Stock profile
Incyte Corporation logo

Incyte Corporation (INCY)

Country: United States of AmericaSector: HealthcareIndustry: BiotechnologyExchange: NASDAQ
P/E TTM
61.0
History
P/E NTM
15.3
Market cap
23.37B
Currency USD
KvantraRankAbout52
IValue42
IIQuality77
IIIMomentum32
Current price
114.63 USD-1.07%
Close 20 Nov 2026
Interval
Benchmarks

Key financial summary

Financials in USD
202020212022202320242025TTM2026E
Total revenue$m2,6672,9863,3953,6964,2415,1416,0116,044
Operating profit$m1,343698
Net profit$m-296949341598331,287403700
EPS reported$6.411.88
Operating cashflow per share$7.243.67
Capex per share$0.300.30
FCF per share$6.943.37
Free cash flow$m1,355685
Net debt$m-3,540-3,817
Book value equity$m5,1675,643
Book value per share$25.7527.76
Number of sharesm200.7203.25
DPS (TTM paid)$0.000.00

Financial summary

Financials in USD
202020212022202320242025TTM2026E
Value
P/E TTMx15.4160.97
P/B LTMx3.734.14
P/S LTMx3.753.89
P/FCF LTMx14.2334.12
EV/EBITDA LTMx9.2222.40
EV/Sales LTMx3.163.25
Earnings Yield LTM%6.49%1.64%
FCF Yield%7.03%2.93%
Quality
ROE%24.90%7.11%
ROIC%19.04%6.03%
Operating margin%26.12%11.61%
Gross margin%92.76%92.69%
FCF/Sales%26.35%11.39%
Growth and momentum
EPS Growth YoY%--68.51%
Sales Growth YoY%+21.22%+24.88%
Net Income Growth YoY%+3845.0%-66.06%
FCF Growth%+443.87%-42.79%
Operating Profit Growth%+1225.6%-44.46%
Dividend and capital structure
Dividend Yield%0.00%0.00%
Dividend Growth%0.00%0.00%
Payout Ratio%0.00%0.00%
FCF/Debtx33.5218.31
Net Debt/EBITDAx-1.74-3.71
EBIT/Net interestx553.04298.53
Net debt/market cap%-18.36%-16.34%
Net debt/Equityx-0.69-0.68
Gross debt/equityx0.010.01

ETFs that hold Incyte

FundTickerPosition#Weight
Fidelity Small-Mid Multifactor ETFFSMD30.38%
Invesco S&P 500 GARP ETFSPGP71.82%
First Trust Large Cap Growth AlphaDEX FundFTC90.95%
First Trust Multi Cap Growth AlphaDEX FundFAD90.46%
iShares Genomics Immunology and Healthcare ETFIDNA103.45%
WisdomTree Strategic Metals UCITS ETF - USD AccWENU.L94.58%
Amplify AI Powered Equity ETFAIEQ93.81%

Funds with Incyte among their ten largest holdings, largest fund first.

Price target estimates

Low estimate
High estimate
Price consensus
Last year average price target
Current price114.63 USD
Return Potential

Based on consensus from external analysts. Not Kvantra's opinion.

Ratings

Strong Buy
Buy
Hold
Sell
Strong Sell
Number of covering analysts

Based on consensus from external analysts. Not Kvantra's opinion.

ESG

Metric202420252026
ESG-score
Environmental score
Social score
Governance score
Risk rating

Company overview

Incyte Corporation is a biopharmaceutical firm engaged in the research, development, and global marketing of its own innovative therapies. Its current product offerings include JAKAFI, prescribed for myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that targets oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor utilized for chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia. Beyond its marketed drugs, Incyte's pipeline features several promising candidates. Among its clinical-stage assets are ruxolitinib, targeting steroid-refractory chronic graft-versus-host disease (GVHD), and itacitinib, which is undergoing Phase II/III trials for newly diagnosed chronic GVHD. Pemigatinib is also being investigated for conditions such as bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and other tumor types. Further advancing its research, the company is developing Parsaclisib, currently in Phase II studies for follicular lymphoma, marginal zone lymphoma, and mantle cell lymphoma. Additionally, Retifanlimab is in Phase II development for multiple indications, including MSI-high endometrial cancer, Merkel cell carcinoma, anal cancer, and non-small cell lung cancer. Incyte maintains a broad network of strategic alliances with numerous pharmaceutical and biotech companies, including key partners like Novartis International Pharmaceutical Ltd., Eli Lilly and Company, and Agenus Inc., among many others. These collaborations extend to clinical trials, notably joint efforts with MorphoSys AG and Xencor, Inc., to evaluate a combination therapy involving tafasitamab, plamotamab, and lenalidomide for patients with recurrent or resistant diffuse large B-cell lymphoma and follicular lymphoma. Established in 1991, the corporation's main offices are situated in Wilmington, Delaware.

Websiteincyte.com
Trades inUSD

Similar companies

For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.

Incyte Corporation (INCY)

INCY · NASDAQ · Healthcare
114.63 USD-1.07%
Sign up to track this stock
Benchmarks
KvantraRank52
Market cap23.37B
P/E NTM15.3
P/E TTM61.0
KvantraRank?52 / 100
Value
42
Quality
77
Momentum
32
Financialsin USD
20242025TTM2026E
ETFs that hold Incyte
FundTickerPosition#Weight
Fidelity Small-Mid Multifactor ETFFSMD30.38%
Invesco S&P 500 GARP ETFSPGP71.82%
First Trust Large Cap Growth AlphaDEX FundFTC90.95%
First Trust Multi Cap Growth AlphaDEX FundFAD90.46%
iShares Genomics Immunology and Healthcare ETFIDNA103.45%
WisdomTree Strategic Metals UCITS ETF - USD AccWENU.L94.58%
Amplify AI Powered Equity ETFAIEQ93.81%

Funds with Incyte among their ten largest holdings, largest fund first.

Analyst target
Consensus
Current114.63 USD
Upside
Price consensus
Last year average price target
Current price114.63 USD
Return Potential

Consensus from external analysts. Not Kvantra's opinion.

Ratings
Strong Buy
Buy
Hold
Sell
Strong Sell

Based on consensus from external analysts. Not Kvantra's opinion.

ESG
202420252026
ESG-score
Environmental score
Social score
Governance score
Risk rating
About

Incyte Corporation is a biopharmaceutical firm engaged in the research, development, and global marketing of its own innovative therapies. Its current product offerings include JAKAFI, prescribed for myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that targets oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor utilized for chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia. Beyond its marketed drugs, Incyte's pipeline features several promising candidates. Among its clinical-stage assets are ruxolitinib, targeting steroid-refractory chronic graft-versus-host disease (GVHD), and itacitinib, which is undergoing Phase II/III trials for newly diagnosed chronic GVHD. Pemigatinib is also being investigated for conditions such as bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and other tumor types. Further advancing its research, the company is developing Parsaclisib, currently in Phase II studies for follicular lymphoma, marginal zone lymphoma, and mantle cell lymphoma. Additionally, Retifanlimab is in Phase II development for multiple indications, including MSI-high endometrial cancer, Merkel cell carcinoma, anal cancer, and non-small cell lung cancer. Incyte maintains a broad network of strategic alliances with numerous pharmaceutical and biotech companies, including key partners like Novartis International Pharmaceutical Ltd., Eli Lilly and Company, and Agenus Inc., among many others. These collaborations extend to clinical trials, notably joint efforts with MorphoSys AG and Xencor, Inc., to evaluate a combination therapy involving tafasitamab, plamotamab, and lenalidomide for patients with recurrent or resistant diffuse large B-cell lymphoma and follicular lymphoma. Established in 1991, the corporation's main offices are situated in Wilmington, Delaware.

Websiteincyte.com
IndustryBiotechnology
Trades inUSD

For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.

Unlock all fundamental data

Sign up for Free

Unlock all fundamental data

Sign up for Free